From: Centrosome associated genes pattern for risk sub-stratification in multiple myeloma
Training cohorta | Validation cohorta | |
---|---|---|
No. of patients | 73 | 78 |
Follow-up median (min–max) [month] | 23.6 (0.3–97.0) | 18.6 (0.1–250.0) |
Gender: males–females | 49.3–50.7 % | 55.1–44.9 % |
Age median (range) [years] | 69 (38–84) | 66 (40–90) |
ISS stage: I–II–III | 28.8 %–27.3 %–43.9 % | 24.7 %–35.1 %– 40.3 % |
Durie-Salmon stage: I–II–III | 4.3 %–14.3 %–81.4 % | 3.8 %–29.5 %–66.7 % |
Durie-Salmon substage: A–B | 81.4 %–18.6 % | 75.6 %–24.4 % |
Ig isotype: IgG–IgA–FLC-Non-secr. | 60.3 %–23.5 %–16.2 % | 57.7 %–28.2 %–1.3 %–12.8 % |
Light chains: kapp–lambda | 58.0 %–42.0 % | 53.8 %–46.2 % |
Plasma cell infiltration in bone marrow | 34.4 % (0.8 %–93.6 %) | 36.0 % (2.2 %–81.2 %) |
No. of previous treatment lines | ||
None (first line treatment) | 57.7 % (41/71) | 64.1 % (50/78) |
One | 19.7 % (14/71) | 15.4 % (12/78) |
Two | 8.5 % (6/71) | 10.3 % (8/78) |
More (>2) | 14.1 % (10/71) | 10.3 % (8/78) |
Treatment regimen | ||
Bortezomib-based | 47.8 % (32/67) | 64.9 % (50/77) |
Thalidomide-based | 14.9 % (10/67) | 10.4 % (8/77) |
Lenalidomide-based | 25.4 % (17/67) | 18.2 % (14/77) |
Others | 11.9 % (8/67) | 6.5 % (5/77) |
Treatment response | ||
CR-VGPR-PR-MR-SD-PG | 12.3 %–29.8 %–22.8 %–5.3 %–5.3 %–26.3 % | 10.8 %–20.0 %–27.7 %–7.7 %–4.6 %–29.2 % |
Biochemical parameters | ||
Hemoglobin (g/l) | 105.5 (67.0–151.0) | 95.5 (65.9–146.0) |
Thrombocytes (×109) | 192.0 (33.0–416.0) | 188.5 (55.0–485.0) |
Calcium (mmol/l) | 2.29 (1.74–23.37) | 2.32 (1.75–2.78) |
Albumin (g/l) | 38.2 (21.1–54.1) | 35.7 (17.4–52.2) |
Creatinine (umol/l) | 98.5 (53.0–783.0) | 94.5 (30.0–849.0) |
β2-microglobulin (mg/l) | 4.70 (1.79–42.60) | 4.61 (1.62–50.0) |
Lactate dehydrogenase (ukat/l) | 3.72 (1.53–22.92) | 3.36 (1.14–7.77) |
C-reactive protein (mg/l) | 3.6 (0.0–174.3) | 4.0 (0.0–149.3) |
Monoclonal Ig (g/l) | 29.8 (0.0–92.6) | 30.2 (0.0–85.6) |
Chromosomal abnormality | ||
Deletion 13q14 | 49.2 % (30/61) | 60.0 % (39/65) |
Deletion 17p13 | 8.3 % (5/60) | 13.8 % (9/65) |
Translocation t(4;14) | 46.9 % (15/32) | 44.4 % (16/36) |
Amplification 1q21 | 56.9 % (37/65) | 54.5 % (36/66) |
Hyperdiploidy (H-MM) | 45.5 % (30/66) | 47.0 (17/46) |